Work

CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.tps9132

Authors: Catherine A. Shu, Koichi Goto, Byoung Chul Cho, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, John Xie, Jun Chen, Janine Mahoney, Meena Thayu, Roland Elmar Knoblauch, Leonardo Trani, Joshua Bauml

Institutions: Columbia University Irving Medical Center, National Cancer Center Hospital East, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Carl von Ossietzky Universität Oldenburg, Pius Hospital Oldenburg, National Taiwan University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, University of Pennsylvania

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Research and Development

OpenAlex ID: W3167536287

Cites:

Cited by: 19

Related to: 10